This project, led by Dr. Glanz, is a sub-project of Dr. Katrina Armstrong's Go Grant: Comparative Effectiveness in Genomic Medicine. Increasing adherence to melanoma prevention behaviors among individuals with a familial predisposition to melanoma is an important public health goal. The role of genetic testing for CDKN2A/p16 and MC1R mutations in the management of families with a predisposition to melanoma is uncertain, in part because there is very little evidence about how testing and counseling affects patient concerns and adherence to preventive recommendations. This proof-of-principle study used a randomized trial design to provide early evidence about the comparative effectiveness of genetic testing and counseling on behavioral outcomes by requesting information about family medical history, sun exposure/protection behaviors and knowledge and risk perception of skin cancers as well as providing genetic counseling that includes genetic test results and feedback to those patients in the intervention arm.